Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the era of the obesity pandemic.1,2 Fat accumulation in the liver results from an imbalance between lipid metabolism and intake, partly contributed to by excessive dietary consumption and hepatic de-novo lipogenesis. Currently, researchers and companies are racing to develop novel therapeutics with different mechanisms of action for non-alcoholic steatohepatitis (NASH), targeting lipid metabolism, inflammatory, or fibrotic pathways.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
